couldbebetter Saturday, 01/12/19 09:27:15 AM Re: ChrisInSF post# 171854 0 Post # of 172906 ChrisInSF, I agree with you and Dan. I believe that the best deal we will get may be $30-$40. What gives me pause that I might be wrong are comments from HDGabor who believes a 3 digit price is possible. My hope is that the Pfizer rumour will result in potential bidders getting into the door, now, rather than waiting. HDGabor has been consistent in his view that a deal (or whatever outcome) will most likely be known in the 1st quarter. Over time as the market(s) for Vascepa expands both in the US and in foreign countries, the price of Vascepa should decline. For example, once approved in Canada, the government there will negotiate a lower price. The same for other countries where the government picks up the tab. In China, it was suggested in an analyst opinion, that the retail price might have to go to $1.00 per day to be viable. Not suggesting that will be the case, but discounting will happen and any BP making its own internal projections is aware of that. When I run through the numbers in my own model I do not think BP will give AMRN the huge valuation that many here expect. As I go over the lists of potential buyers, and it is fun to speculate, I think it will be a company with a strong cardiovascular sales/rep force.